The manufacturing lot evaluation confirmed all devices met specifications prior to release.The device was not returned as the device remains implanted therefore no evaluation was completed.At the completion of the clinical assessment, clinical was able to find substantial evidence to support the following finding of the main body stent collapse and sac growth.Clinical was able to find substantial evidence to support the following additional findings of type iiia endoleak with complete component separation.Due to the lack of relivent medical records, clinical was unable to confirm the reported event of urgent presentation, treated with non- endologix device and fem-fem bypass graft during the secondary endovascular procedure.Device, user, procedure or anatomy relatedness and procedure related harms of this complaint could not be determined based on the information shared with endologix to review.The final patient status was reported to be stable.Endologix continues to investigate this event and similar events to ensure the highest quality and patient safety.
|